Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS

Introduction. Favipiravir is one of the most well-known broad-spectrum drugs against many RNA viruses, including severe acute respiratory syndrome virus 2 [severe coronavirus (SARS-CoV-2)]. Due to its structure, favipiravir embedded in and blocks further replication cell human body. also included list vital essential medicines, which confirms importance for Russian healthcare this drug fight common viruses. We have already published bioanalytical methods determining blood plasma by high-performance liquid chromatography with an ultraviolet detector (HPLC–UV) order study pharmacokinetics parenteral administration (the analytical range technique was 0.25–200.00 µg/ ml dosage 400 mg 1 vial lyophilizate preparation concentrate solution infusions) HPLC tandem mass-selective detection (HPLC-MS/MS) β-D-N4-hydroxycytidine their joint determination oral 250.00–20000.00 ng/ml tablet). The expectation low favipiravir’s concentrations question 200 tablet study) and, regard, expansion reducing value lower limit quantitative (LLOQ) used necessitates development another method. Therefore, given validation a method HPLC-MS/MS 50.00–15000.00 ng/ml. Aim. aim develop researches bioequivalence drugs. Materials methods. In process sample preparation, proteins precipitation methanol used. A labeled stable isotopes favipiravir-13C3 as internal standard, mobile phase 0.1 % formic acid water (eluent A) B). Chromatographic column – Phenomenex Kinetex C18, 100×3.0 mm. carried out using mass spectrometric triple quadrupole. 50.00– 15000.00 plasma. Results discussion. This validated selectivity, calibration curve, accuracy, precision, matrix effect, spike recovery, carry-over quantification stability. Conclusion. confirmed has been developed validated. allows it part studies containing expand domestic pharmaceutical market.